Reviewer’s report

**Title:** Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells

**Version:** 2  **Date:** 13 January 2010

**Reviewer:** gregoire prevost

**Reviewer’s report:**

The submitted paper is well prepared with a serious and classical experimental and scientific approach. The topic is original and will bring more and more attention to the scientists for defining new drug targets. This paper should be published in its current form. However, May I suggest few points to introduce or discuss in the paper.

1) More information on the levels of expression of the considered proteins in human cancers (breast or other tissues NSCLC) should be added if available or discussed why if not. Cancer usually treated by tubulin binders.

2) The experimental model is a steroid receptor positive cell line usually using to study antihormonal therapeutic approach for breast cancer. Why the authors have selected this model rather than using steroid receptor negative cell lines (ie MDA MB231).

3) The change of drug sensitivity following the change of level expression should be challenged with anticancer drugs acting through a different mechanism - ie topoisomerase inhibitors or Platinum.

4) Suggestion on how manipulate this new target should be proposed to identify new modulators.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests.